Roumen Balabanov, MD
Neurology · Chicago, ILNPI 1508817941
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,214 of the $136,394 with a category attached, or 74.9%. Biogen accounts for 92.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $104,525 and has fallen 99.7% since, to $306 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $1498.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$126K
- AstraZeneca$5K
- Genentech USA, Inc.$5K
- TG Therapeutics, Inc.$306
- EMD Serono, Inc.$145
- Genentech, Inc.$40
- plus $19 from 1 others
Across 7 payments — averaging $97,460 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$682K
What the payments were for
- Consulting fees$26,95320%
- Speaking & faculty fees$102,21475%
- Travel & lodging$4,7964%
- Food & beverage$2,3912%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 76 | $125,987 |
| AstraZeneca | 5 | $5,314 |
| Genentech USA, Inc. | 2 | $4,583 |
| TG Therapeutics, Inc. | 5 | $306 |
| EMD Serono, Inc. | 1 | $145 |
| Genentech, Inc. | 1 | $40 |
| Sanofi | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,394 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 35 | $317,103 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 51 | $279,493 |
| VumerityDiroximel Fumarate | 30 | $224,228 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $193,835 |
| CopaxoneGlatiramer Acetate | 26 | $143,129 |
| AubagioTeriflunomide | 12 | $105,308 |
| Glatiramer Acetate | 12 | $69,336 |
| Dimethyl Fumarate | 32 | $42,719 |
| Dalfampridine ErDalfampridine | 71 | $31,921 |
| Mycophenolate Mofetil | 79 | $8,703 |
| MyrbetriqMirabegron | 11 | $5,902 |
| Baclofen | 84 | $2,283 |
| ValacyclovirValacyclovir Hcl | 24 | $1,324 |
| Duloxetine Hcl | 17 | $1,252 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $1,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Vumerity | $125,987 | $541,33165 claims |
| SanofiAubagio | $19 | $105,30812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Chicago
- Augusto MiravalleChicago$1.4M
- Adil JavedChicago$584K
- Danny BegaChicago$442K
- Michael SmithChicago$382K
- Dusan StefoskiChicago$294K
- Veronica CiprianiChicago$289K
- Thomas ShoemakerChicago$278K
- Bruce CohenChicago$276K
- Margaret ParkChicago$245K
- Leonard Verhagen MetmanChicago$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.